Lilly And Medtronic In Parkinson’s Pact | May 2, 2011 Issue - Vol. 89 Issue 18 | Chemical & Engineering News
Volume 89 Issue 18 | p. 15 | Concentrates
Issue Date: May 2, 2011

Lilly And Medtronic In Parkinson’s Pact

Department: Business
Keywords: Parkinson’s disease, drug delivery

Eli Lilly & Co. has joined with Minneapolis-based device maker Medtronic to deliver a neurotrophic-factor-based therapy in the brains of people with Parkinson’s disease. Lilly has biosynthetically engineered a variant of glial-cell-derived neurotrophic factor (GDNF), a protein that promotes the growth and survival of brain cells. In the past, GDNF was difficult to administer as a gene therapy because of its inability to cross the blood-brain barrier. Under the collaboration, Medtronic will use its implantable drug infusion system technology to deliver the Lilly compound.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment